Wednesday, August 21, 2019

Innovent Enters a Licensing Agreement with Lilly to Develop & Commercialize a Novel Diabetes Medicine in China

SUZHOU, China, Aug. 21, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that it has entered into a licensing agreement with Eli Lilly and Company...



from PR Newswire: https://ift.tt/2Z9isxI

No comments:

Post a Comment